abstract |
A modified release pharmaceutical composition comprises 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier. The composition is adapted to provide a plasma concentration of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione within the range of from 40 to a level at or above 130 ng/mL over a sustained period of time such as a time period of up to 24 hours. The composition can be a delayed, pulsed or sustained release composition. (62) Divided out of 511610 |